Want to see MCK full AI Analyst Report?
MCK Stock Chart & Stats
$840.90
$16.41(1.99%)
At close: 4:00 PM EDT
$840.90
$16.41(1.99%)
Day’s Range― - ―
52-Week Range$637.00 - $999.00
Previous CloseN/A
Volume823.78K
Average Volume (3M)1.05M
Market Cap
$100.24B
Enterprise Value$112.06K
Total Cash (Recent Filing)$3.98B
Total Debt (Recent Filing)$8.61B
Price to Earnings (P/E)22.2
Beta0.18
Next Earnings
Aug 05, 2026EPS Estimate
9.56Next Dividend Ex-DateN/A
Dividend Yield0.38%
Share Statistics
EPS (TTM)38.64
Shares Outstanding117,077,740
10 Day Avg. Volume868,018
30 Day Avg. Volume1,049,213
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)-49.24
Price to Sales (P/S)0.27
P/FCF Ratio18.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$937.09Price Target Upside11.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)44.26
Revenue Forecast (FY)$431.21B
Bulls Say, Bears Say
Bulls Say
Scale & Revenue GrowthSustained, large-scale revenue growth underscores McKesson’s dominant distribution scale and broad customer relationships. That scale supports durable purchasing leverage with manufacturers, high fixed-cost absorption across logistics, and resilience to demand shifts — advantages that persist over multiple quarters.
Strong Cash Generation & Capital AllocationConsistent operating and free cash flow provide structural capacity to fund share repurchases, dividends, and strategic investments. Strong cash conversion lets management prioritize balance-sheet repairs and separation financing while preserving the ability to invest in automation and specialty services over the medium term.
Oncology & Specialty MomentumRapid, scalable growth in oncology and multispecialty services diversifies McKesson away from low‑margin commoditized distribution. Provider additions, targeted acquisitions and higher-value service lines can sustainably lift segment operating profit and reduce exposure to branded/generic pricing cycles over the coming quarters.
Bears Say
Structurally Thin MarginsVery low gross and net margins mean limited slack for cost inflation, pricing pressure, or mix shifts. Even modest declines in purchasing spreads or increased operating costs can disproportionately erode earnings, making profitability sensitive despite high revenue scale and increasing the importance of higher‑margin specialty growth.
Legacy Balance Sheet Weakness & LeverageAlthough equity has turned positive, the prior negative-equity history and meaningful leverage constrain financial flexibility. Dependence on external financing and a meaningful debt load raise refinancing and covenant risk, complicating large corporate actions like the Medical‑Surgical separation and limiting downside protection.
Free Cash Flow Volatility & Separation-Related CostsMaterial FCF volatility reduces predictability for buybacks, dividends and separation funding. Planned separation financing and higher interest expense compress near‑term cash available for operations and investments, increasing execution risk and elevating sensitivity to working‑capital swings in distribution.
McKesson News
MCK FAQ
What was Mckesson Corp.’s price range in the past 12 months?
Mckesson Corp. lowest stock price was $637.00 and its highest was $999.00 in the past 12 months.
What is Mckesson Corp.’s market cap?
Mckesson Corp.’s market cap is $100.24B.
When is Mckesson Corp.’s upcoming earnings report date?
Mckesson Corp.’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were Mckesson Corp.’s earnings last quarter?
Mckesson Corp. released its earnings results on May 07, 2026. The company reported $11.69 earnings per share for the quarter, beating the consensus estimate of $11.565 by $0.125.
Is Mckesson Corp. overvalued?
According to Wall Street analysts Mckesson Corp.’s price is currently Undervalued.
Does Mckesson Corp. pay dividends?
Mckesson Corp. pays a Quarterly dividend of $0.94 which represents an annual dividend yield of 0.38%. See more information on Mckesson Corp. dividends here
What is Mckesson Corp.’s EPS estimate?
Mckesson Corp.’s EPS estimate is 9.56.
How many shares outstanding does Mckesson Corp. have?
Mckesson Corp. has 117,077,740 shares outstanding.
What happened to Mckesson Corp.’s price movement after its last earnings report?
Mckesson Corp. reported an EPS of $11.69 in its last earnings report, beating expectations of $11.565. Following the earnings report the stock price went down -2.474%.
Which hedge fund is a major shareholder of Mckesson Corp.?
Currently, no hedge funds are holding shares in MCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
McKesson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$937.09 (11.44% Upside)
$937.09 (11.44% Upside)
Blogger Sentiment
Bullish
MCK Sentiment 78%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 323.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.90%
12-Months-Change
Fundamentals
Return on Equity
0.38%
Trailing 12-Months
Asset Growth
9.56%
Trailing 12-Months
Company Description
Mckesson Corp.
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
MCK Company Deck
MCK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
McKesson reported a strong fiscal 2026 with double-digit revenue, operating profit and EPS growth, robust cash generation and material progress on strategic initiatives (oncology expansion, biopharma scale, supply chain modernization, and Medical‑Surgical separation). The company is returning significant capital to shareholders and reaffirmed long‑term targets. Offsetting risks include branded pricing pressure (IRA effects), sequential GLP‑1 volatility, ongoing integration and corporate expense investments, and near‑term cash flow/interest impacts related to separation financing. On balance the positives (broad-based growth, margin expansion, cash returns, strategic progress) outweigh the negatives, though the business faces near-term variability and execution/approval risks tied to the Medical‑Surgical separation.View all MCK earnings summariesMCK Revenue Breakdown
83.45% North American Pharmaceutical
12.00% Oncology & Multispecialty
1.44% Prescription Technology Solutions
2.85% Medical-Surgical Solutions
0.26% Other
MCK Stock 12 Month Forecast
Average Price Target
$937.09
▲(11.44% Upside)
Technical Analysis
Cencora
―
Cardinal Health
―
Henry Schein
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
0.04% Insiders
24.04% Mutual Funds
2.81% Other Institutional Investors
49.10% Public Companies and Individual Investors